Search

everythinglearnresearchcommunity

for

Search:↓

Patients with PCOS rate their hirsutism higher than clinicians, and these self-ratings are more closely related to their quality of life and risk of depression.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Parthenolide promotes hair growth in mice and may influence pathways related to male pattern baldness.

Testosterone replacement can help women with low libido and mood, but they need to have enough estrogen first to avoid side effects.

The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Men with more vanadium in their blood and who drink less soy milk are more likely to have hair loss.

Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.

5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

Early diagnosis and treatment can reduce cicatricial alopecia in middle-aged individuals, especially females.

Hydroxychloroquine may help delay skin damage in lupus patients.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

Hormonal changes and psychological issues can cause sexual dysfunction in postmenopausal women. Behavioral therapy is recommended first, with hormone replacement helping some symptoms but not libido. Testosterone can improve libido, but its effects on overall sexual function are unclear. Emotional and relationship issues should be addressed before using medication, and the benefits and risks of testosterone supplementation should be considered.

Postmenopausal ovary stromal cells have a unique makeup and limited steroid production, suggesting androgens come from the adrenal gland.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

Ginseng is possibly safe but its effectiveness is unclear due to poor quality studies and mixed results.

PCOS symptoms change with age; younger women have higher androgen levels and less metabolic issues, while older women face more metabolic challenges despite milder PCOS symptoms.

Sleep problems and skin issues affect each other; poor sleep can worsen skin conditions, and some skin treatments can improve or harm sleep quality.

Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.

Dermoscopy effectively assesses and improves acne scar treatments.

Low dose finasteride decreases certain steroids, possibly increasing depression risk.

Researchers found 71 genetic regions linked to male pattern baldness, which account for 38% of its genetic risk.